GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Ceftolozane / tazobactam (Zerbaxa)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Record caution: Label-version change: the May 2026 DailyMed pediatric renal table is now local. Older pediatric evidence-gap statements remain historical; read the new age-specific source before selecting a regimen.

U.S. labeling, UCSF and Nebraska distinguish indication and infusion duration. Nebraska uses a 4-hour inpatient infusion; the label uses 1 hour. Keep each renal table with its indication and infusion method.

Check source scope before reading a dose

ZERBAXA - adult indication-specific renal table

Product / population
Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.
Renal method
Cockcroft-Gault CrCl, mL/min.
Source revision
Label updated 2026-05-12; dosing changes May 2026.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

One-hour labeling versus institutional extended infusion

The RX label table uses a one-hour infusion. The UCSF protocol uses a three-hour infusion. Both also separate urinary/intra-abdominal infection from pneumonia/severe infection.

What to reconcile: Keep the selected source dose, indication, renal band, loading instruction and infusion duration together.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

Pediatric renal guidance changed after the RX mirror

The older mirror lacks the age-specific renal regimens now supplied by the May 2026 label.

What to reconcile: Use the new pediatric card for ages two and older; verify indication, pediatric eGFR, weight caps and infusion time. Do not use adult Cockcroft-Gault bands as pediatric instructions.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Official

ZERBAXA - adult indication-specific renal table

Open original reference

NIH/NLM DailyMed - U.S. product labeling · Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl, mL/min.
Source date: Label updated 2026-05-12; dosing changes May 2026.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

All adult doses are total combination amounts, IV every 8 hours over 1 hour. For cIAI/cUTI, baseline is 1.5 g; for HABP/VABP, 3 g. Add metronidazole for cIAI.

CrCl (mL/min)cIAI/cUTI doseHABP/VABP dose
30-50750 mg1.5 g
15-29375 mg750 mg
<15 without IHDNot establishedNot established
IHD750 mg loading, then 150 mg every 8 hours2.25 g loading, then 450 mg every 8 hours

On IHD days administer as soon as possible after completion. Monitor changing CrCl at least daily. The 51-to-<90 label band retains baseline doses. Pediatric renal and infusion schedules are separate and must not be inferred from these adult doses.

RDM30-068-ceftolozane-tazobactam-1 · Source locator: ZERBAXA - adult indication-specific renal table; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70ac1d90-eff3-4f0b-9f46-5846c571b32f
Retrieved
2026-09-05
DailyMed Set ID
70ac1d90-eff3-4f0b-9f46-5846c571b32f
Renal-function method
Cockcroft-Gault CrCl, mL/min.
Source date/version
Label updated 2026-05-12; dosing changes May 2026.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
a538b6193030702f3a44c9683248f19e1897e79c706307bd19c333b9f1636885

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ceftolozane-tazobactam&s1=RDM30-068-ceftolozane-tazobactam&h1=ebbfa3c696b52c2e496ac86f4e765c10017834bd175d1b1233e46f83a4de46a9